Clinical trial
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in…
NCT00428142 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00428142 |
|---|---|
| Title | Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma |
| Official title | A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone, and Rituximab (BCVP-R) for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, bortezomib, cyclophosphamide, prednisone, vincristine sulfate |
| Enrollment | 95 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2011 |
| Completion | Jan 6, 2012 |
| First posted | Jan 29, 2007 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: